We have studied an acute promyelocytic leukemia (APL) patient with a variant t(5;17)(q32;q12). This translocation fuses the gene for the nucleolar phosphoprotein nucleophosmin (NPM) to the retinoic acid receptor a (RARA). Two alternatively spliced transcripts are expressed, which differ in 129 bases immediately upstream of the RARA sequence. The NPM sequences contained in the shorter NPM-RAR cDNA are identical to the NPM sequences contained in the NPMALKfusion gene expressed in t(2;5) lymphomas. The RARA sequences are the same as the RARA sequences found in the PML-RAR and PLZF-RAR fusion seen in t(15;17) and that fuses the zinc finger protein PLZF to RARA" has been seen in rare patients. PLZF-RAR contains the same domains of RARA as are contained in PML-RAR. The t( 1 1 ; 17) variant differs from t( 15; 17) APL both in blast morphology and response to retinoic acid."
t(11;17) APL, respectively. Both NPM-RAR transcripts fuse NPM and RARA sequence in the same reading frame, to generate translation products of 57 kD and 62 kD. Both NPM-RAR proteins are expressed in the patient's leukemic cells, along with wild-type RARA derived from the uninvolved allele. In transcriptional assays using a retinoic acid response element reporter construct, both NPM-RAR fusion proteins act as retinoic acid-dependent transcriptional activators. This case defines a third class of APL rearrangements, all of which generate fusion proteins of R A M . 0 1996 by The American Society of Hematology.
that fuses the zinc finger protein PLZF to RARA" has been seen in rare patients. PLZF-RAR contains the same domains of RARA as are contained in PML-RAR. The t( 1 1 ; 17) variant differs from t( 15; 17) APL both in blast morphology and response to retinoic acid. " We have previously reported a patient13 with APL which exhibited a t(5; 17)(q32;q12). Southern blotting analysis of bone marrow (BM) DNA showed rearrangement of the RARA IOCUS.'~ Cloning of the fusion cDNA reveals that t(5; 17) results in expression of a novel chimeric transcript that joins the 5' end of nucleophosmin (NPM) with the 3' end of RAM. A major nucleolar phosphoprotein, NPM has been previously identified as a fusion partner with the ALK tyrosine kinase in Ki-l lymphomas associated with t(2;5).IJ In our patient with APL, the t(5;17) gives rise to a fusion protein that acts as a retinoic acid-responsive transcriptional activator.
MATERIALS AND METHODS
Cuse report. We reported a 2'/* year old girl with APL and a t(5; 17)(q32;q12) chromosomal translocation.'' The patient was treated initially with daunorubicin, cytosine-arabinoside, 6-thioguanine, and etoposide. Four months after presentation a morphologic remission was achieved, but cytogenetic analysis showed persistence of cells with the t(5; 17). She began a 60-day course of all-trans retinoic acid (45 mg/m2/d), which resulted in normalization of the BM karyotype. However, the leukemia recurred with the same cytogenetic abnormality. She received an autologous BM transplant, but her leukemia recurred and remained refractory to further chemotherapy.
Cloning of NPM-RAR cDNA. Polyadenylated RNA was prepared from the BM obtained at diagnosis and used to generate a Lambda Zap I1 cDNA library (Stratagene, La Jolla, CA). The library was screened with a radiolabelled RARA cDNA probe under highstringency conditions. Positive clones were plaque purified, and clones that were consistent with a rearranged RARA cDNA were sequenced using cycle sequencing with an AB1 373 sequencer (Applied Biosystems, Foster City, CA). Homology searches of both GenBank and EMBL databases were performed using the FASTA algorithm.
Transfection assuys. CV 1 cells and COS cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS; Paragon Biotech, Baltimore, MD) and gentamicin. Transient transfection was performed using either calcium phosphateI5 or Lipofectamine (GIBCO, Grand Island, 
RESULTS

t(5; 17) generates two NPM-RAR chimeric cDNAs.
Sequencing of clones from the cDNA library revealed two rearranged RARA species (Fig 1) . These represent transcripts of 2.3 kb and 2.4 kb. Corresponding bands were detected in Northern blots of the leukemic cells (not shown). We will refer to the two cDNAs as NPMsRAR (short) and NPM,-RAR (long) (GenBank accession nos. U41743 and U41742, respectively). Both have 5' ends that correspond to the first 442 bases of the NPM cDNA. Southern blot analysis of the patient's DNA with an NPM probe confirmed rearrangement of the NPM locus (not shown).
The 3' end of NPMrRAR cDNA contains RARA sequence that codes for exon 3 through the 3' end of RARA. This indicates that the breakpoint lies within the second intron of RARA, the same region as in the t( 15; 17) and t( l 1; 17) translocations.2.'R Thus, NPM,RAR cDNA contains the same RARA sequences as PML-RAR and PLZF-RAR. NPM,-RAR differs from NPM,RAR in that it contains an additional 50 bases of NPM that correspond to the 5' end of rat'9 NPM exon 5 (Fig 1) . This is followed by 79 bases of sequence that bear no homology to sequences in the GenBank or EMBL databases (human NPM genomic sequence has not been published).
The library screen also identified a reciprocal RAR-NPM transcript with RARA exons 1 and 2 at the 5' end fused to 3' NPM sequence downstream of NPM base 443. Wild-type RARA cDNA was also amplified from the cDNA library by polymerase chain reaction (data not shown). Protein expression. Both forms of NPM-RAR fuse NPM and RARA coding sequences in the same reading frame to generate predicted translation products of 520 and 563 amino acids, and deduced protein sizes of 57 kD and 62 kD, respectively. In vitro transcription and translation of the two cDNAs generated bands appropriate for proteins of 57 kD and 62 kD, which could be immunoprecipitated with either anti-RARA or anti-NPM antiserum (data not shown). To determine whether the longer form represents an unspliced Arrows indicate the bands that correspond t o wild-type RARA and the NPML-RAR and NPM,-RAR proteins. The PML-RAR protein expressed in NB4 is also indicated with an arrow.
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precursor of the shorter transcript, both cDNAs were subcloned into the pSG5 expression vecto?" and transfected into COS cells. Immunoblots showed a 57-kD protein in cells transfected with NPMs-RAR, and a 62-kD band in cells transfected with NPML-RAR (Fig 2) . The lack of the 57-kD species in cells transfected with the NPM,-RAR expression plasmid suggests that NPML-RAR is not a precursor of NPM,-RAR, but rather that it represents an alternatively spliced transcript. Expression of NPM-RAR fusion proteins in the patient's marrow. Immunoblotting of cell lysates of the patient's leukemic marrow with an anti-RARA antiserum identified wild-type RARA and two rearranged proteins that match the sizes of the two predicted NPM-RAR species (Fig 3) . Both fusion proteins are expressed at similar levels which are higher than that of wild-type RARA. The apparent decrease in wild-type RARA signal intensity in the BM versus HL-60 and NB4 lanes of Fig 3 reflects a lower NPM-RAR acts as a transcriptional activator. To determine whether NPM-RAR might function as a retinoic aciddependent transcriptional activator, we assessed its ability to activate expression from a retinoic acid-inducible promoter.
Expression vectors containing the cDNA for RARA (gift of P. Chambon), NPM,-RAR, NPM,RAR, or no insert were transfected into CV1 cells along with the retinoic acid reporter construct RARP-CAT (gift of R.M. Evans, Salk Institute, La Jolla, Ca) and RSV-luciferase. Transiently transfected cells were stimulated with retinoic acid at concentrations up to IO-' moIL.
CAT assays show that both forms of NPM-RAR have only modest activity as transcriptional activators in the absence of retinoic acid (Fig 4) . This activity increases eightfold in the presence of retinoic acid, in a concentration-dependent manner that mimics wild-type RARA. Both forms of NPM-RAR show similar dose-response curves. Experiments using another retinoic acid inducible reporter construct (tk-TREp-CAT) showed similar results (not shown).
DISCUSSION
We have evaluated on a molecular level a patient with APL with a translocation involving chromosomes 5 and 17. This translocation results in expression of a fusion cDNA involving nucleophosmin and the retinoic acid receptor a. Two NPM-RAR cDNAs are expressed. Both contain NPM and RARA sequences in the same reading frame to encode proteins of 57 kD and 62 kD, respectively. Both proteins are expressed in the patient's leukemic cells. Both forms behave as retinoic acid-dependent transcriptional activators.
Nucleophosmin is a major nucleolar phosphoprotein. NPM maps'4 to 5q35, consistent with the cytogenetic breakpoint found in this patient. NPM protein localizes to For personal use only. on August 30, 2017 . by guest www.bloodjournal.org From
t(5;17) APL EXPRESSES AN NPM-RAR FUSION
the granular portion of the nucleolus" and is presumed to play a role in ribosomal RNA processing or transport. This phosphoprotein has four functional motifs: a putative metal binding site, a phosphorylation site, and two large acidic The acidic loops are deleted in the NPM-RAR fusion proteins that we have identified. The phosphorylation site is maintained in NPML-RAR but deleted in NPMs-RAR. Because both forms of NPM-RAR show the same ability to induce transcription, it appears unlikely that phosphorylation at the NPM phosphorylation (deleted in NPMs-RAR) is required for transcriptional activity.
NPM expression has been linked to cell proliferation. It is enriched in actively dividing cells,z5 its synthesis increases rapidly after mitogenic s t i m~l a t i o n ,~~ and its levels decrease during apoptosis." Rearrangement of NPM has previously been reported in t(2;5) Ki-l lymphomas, in which NPM is fused to the ALK tyrosine kinase.14 The NPM sequences in the NPM-ALK and NPM,-RAR transcripts are identical. NPM is also fused to a novel gene called MLFl in t(3;5) myelodysplastic syndrome^.'^ NPM-MLF1 contains 175 N-terminal amino acids of NPM (58 amino acids more than NPM-ALK or NPMs-RAR) and localizes to the nucleolus. 24 Joined to the N-terminal elements of NPM in both NPM-RAR proteins are the RARA DNA binding, heterodimerization, and ligand binding domains (Fig l) , the same portion of RARA contained in PML-RAR3,4327 and PLZF-RAR. 28 We have shown that both forms of NPM-RAR act as transcriptional activators of retinoic acid-responsive genes. This contrasts with the poor transactivation abilities of artificial Nterminal truncation mutants of R A R A . 2 9 PML-RAR also functions as a ligand-dependent transcriptional activator, though its activity varies with both the target cell line and reporter c o n s t r~c t .~,~.~~.~~ In contrast, PLZF-RAR has not been shown to have transactivating properties.28 It is conceivable that this difference might contribute to the variant phenotype of cells expressing t(l1; 17). NPM-RAR may have other biologic functions not attributable to its retinoic acid-dependent transcriptional properties. RARA and PML-RAR alter the function of the AP-1 transcription factor": because NPM-RAR possesses the same RARA sequences that are presumed necessary for AP-1 interaction, the NPM-RAR fusion proteins might affect cells through a similar pathway of nuclear signaling "cross-talk.'' NPM forms oligomer^,^' and it is possible that NPM-RAR may oligomerize with itself or wild-type NPM. It is tantalizing to speculate that NPM-RAR may localize to the nucleolus and alter the subcellular localization of RARA binding partners, thus indirectly affecting wild-type RARA function as has been shown for PML-RAR.8,9 It is also conceivable that NPM-RAR might interact with wild-type PML protein in the nuclear matrix3' to alter the nuclear compartmentalization of the PML p r~t e i n~.~ and disrupt assembly of the nuclear bodies or "PODS" that have been postulated to be critical for myeloid differentiation. ' Similar to many cases of t(l5; 17)3.4.33,34 and t(l1; 17)" APL, a reciprocal translocation product was also identified in the t(5; 17) cDNA library. This transcript fuses 5' RARA sequence in frame with 3' NPM sequence to generate a putative fusion protein with molecular weight 
